Alphabet To Rally Around 14%? Here Are 10 Top Analyst Forecasts For Monday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst…
Protara Therapeutics Shares Interim Data From Bladder Cancer Study, Raises $45M Via Equity
Explore TARA-002's data in NMIBC treatment. Discover findings from three trials, including response rates, adverse events, and future plans. Stay updated on Protara Therapeutics' advancements in cancer therapy and FDA alignment for Choline Chloride.
12 Health Care Stocks Moving In Friday’s Pre-Market Session
Gainers Protara Therapeutics (NASDAQ:TARA) stock increased by 40.3% to $5.64 during Friday’s pre-market session. The market value of…
Protara Therapeutics Announces Oversubscribed $45M Private Placement Financing
Protara Therapeutics, Inc. (NASDAQ:TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced that it has entered into a subscription agreement
12 Health Care Stocks Moving In Monday’s Pre-Market Session
Gainers Pasithea Therapeutics (NASDAQ:KTTA) shares moved upwards by 86.6% to $0.56 during Monday’s pre-market session. The market value…
Protara Therapeutics Announces Presentation Of Additional Encouraging Data From Phase 1a ADVANCED-1 Trial Of TARA-002 In NMIBC At The 24th Annual Meeting Of The Society Of Urologic Oncology
New results from six patients with HGTa papillary tumors show five of six patients with HGRFS at Week 12Data continue to support favorable tolerability of TARA-002 in patients with NMIBC As previously reported,
Stocks That Hit 52-Week Lows On Friday
Friday's session saw 169 companies set new 52-week lows.
Stocks That Hit 52-Week Lows On Friday
Friday's session saw 225 companies set new 52-week lows.